217 related articles for article (PubMed ID: 17726098)
1. Inhibitors of metabolism rescue cell death in Huntington's disease models.
Varma H; Cheng R; Voisine C; Hart AC; Stockwell BR
Proc Natl Acad Sci U S A; 2007 Sep; 104(36):14525-30. PubMed ID: 17726098
[TBL] [Abstract][Full Text] [Related]
2. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms for neuronal cell death and dysfunction in Huntington's disease: pathological cross-talk between the nucleus and the mitochondria?
Sawa A
J Mol Med (Berl); 2001 Jul; 79(7):375-81. PubMed ID: 11466559
[TBL] [Abstract][Full Text] [Related]
4. Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington's Disease human lymphoblasts.
Naia L; Ferreira IL; Cunha-Oliveira T; Duarte AI; Ribeiro M; Rosenstock TR; Laço MN; Ribeiro MJ; Oliveira CR; Saudou F; Humbert S; Rego AC
Mol Neurobiol; 2015 Feb; 51(1):331-48. PubMed ID: 24841383
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast Growth Factor 9 Suppresses Striatal Cell Death Dominantly Through ERK Signaling in Huntington's Disease.
Yusuf IO; Cheng PH; Chen HM; Chang YF; Chang CY; Yang HI; Lin CW; Tsai SJ; Chuang JI; Wu CC; Huang BM; Sun HS; Yang SH
Cell Physiol Biochem; 2018; 48(2):605-617. PubMed ID: 30021209
[TBL] [Abstract][Full Text] [Related]
6. Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington's disease knock-in striatal cells.
Ribeiro M; Rosenstock TR; Oliveira AM; Oliveira CR; Rego AC
Free Radic Biol Med; 2014 Sep; 74():129-44. PubMed ID: 24992836
[TBL] [Abstract][Full Text] [Related]
7. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.
Doria JG; Silva FR; de Souza JM; Vieira LB; Carvalho TG; Reis HJ; Pereira GS; Dobransky T; Ribeiro FM
Br J Pharmacol; 2013 Jun; 169(4):909-21. PubMed ID: 23489026
[TBL] [Abstract][Full Text] [Related]
8. AKT-sensitive or insensitive pathways of toxicity in glial cells and neurons in Drosophila models of Huntington's disease.
Liévens JC; Iché M; Laval M; Faivre-Sarrailh C; Birman S
Hum Mol Genet; 2008 Mar; 17(6):882-94. PubMed ID: 18065778
[TBL] [Abstract][Full Text] [Related]
9. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
[TBL] [Abstract][Full Text] [Related]
10. Increased energy metabolism rescues glia-induced pathology in a Drosophila model of Huntington's disease.
Besson MT; Dupont P; Fridell YW; Liévens JC
Hum Mol Genet; 2010 Sep; 19(17):3372-82. PubMed ID: 20566711
[TBL] [Abstract][Full Text] [Related]
11. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum.
Oliveira JM
J Neurochem; 2010 Jul; 114(1):1-12. PubMed ID: 20403078
[TBL] [Abstract][Full Text] [Related]
12. A novel target for Huntington's disease: ERK at the crossroads of signaling. The ERK signaling pathway is implicated in Huntington's disease and its upregulation ameliorates pathology.
Bodai L; Marsh JL
Bioessays; 2012 Feb; 34(2):142-8. PubMed ID: 22334892
[TBL] [Abstract][Full Text] [Related]
13. Enhanced neuronal glucose transporter expression reveals metabolic choice in a HD Drosophila model.
Besson MT; Alegría K; Garrido-Gerter P; Barros LF; Liévens JC
PLoS One; 2015; 10(3):e0118765. PubMed ID: 25761110
[TBL] [Abstract][Full Text] [Related]
14. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.
Chiang MC; Chern Y; Huang RN
Neurobiol Dis; 2012 Jan; 45(1):322-8. PubMed ID: 21907283
[TBL] [Abstract][Full Text] [Related]
15. Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders.
Bryan MR; Bowman AB
Adv Neurobiol; 2017; 18():113-142. PubMed ID: 28889265
[TBL] [Abstract][Full Text] [Related]
16. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila.
Liévens JC; Rival T; Iché M; Chneiweiss H; Birman S
Hum Mol Genet; 2005 Mar; 14(5):713-24. PubMed ID: 15677486
[TBL] [Abstract][Full Text] [Related]
17. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
[TBL] [Abstract][Full Text] [Related]
18. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.
Seong IS; Ivanova E; Lee JM; Choo YS; Fossale E; Anderson M; Gusella JF; Laramie JM; Myers RH; Lesort M; MacDonald ME
Hum Mol Genet; 2005 Oct; 14(19):2871-80. PubMed ID: 16115812
[TBL] [Abstract][Full Text] [Related]
19. Bioenergetic deficits in Huntington's disease iPSC-derived neural cells and rescue with glycolytic metabolites.
HD iPSC Consortium
Hum Mol Genet; 2020 Jul; 29(11):1757-1771. PubMed ID: 30768179
[TBL] [Abstract][Full Text] [Related]
20. Connectivity mapping uncovers small molecules that modulate neurodegeneration in Huntington's disease models.
Smalley JL; Breda C; Mason RP; Kooner G; Luthi-Carter R; Gant TW; Giorgini F
J Mol Med (Berl); 2016 Feb; 94(2):235-45. PubMed ID: 26428929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
